Related Experiment Videos
[Development and regression of dermal corticosteroid atrophy. 2. Changes in compression rate]
Dermatosen in Beruf Und Umwelt. Occupation and Environment
|November 1, 1986
Summary
Topical corticosteroids cause dermal atrophy by reducing skin hydration and inhibiting fibroblast synthesis of hyaluronic acid and glycosaminoglycans. This skin thinning and reduced compression rate reverses after treatment cessation.
Area of Science:
- Dermatology
- Biochemistry
- Materials Science
Context:
- Steroid-induced dermal atrophy is a known side effect of topical corticosteroid use.
- Understanding the biophysical and biochemical mechanisms is crucial for managing this condition.
- Previous studies focused on the development and remission of atrophy.
Purpose:
- To investigate the biophysical changes in skin fold thickness (SFT) and compression rate (CR) during steroid-induced dermal atrophy.
- To elucidate the underlying biochemical mechanisms, specifically the role of the water/basic substance system and fibroblast synthesis.
- To assess the reversibility of atrophy following cessation of corticosteroid treatment.
Summary:
- A novel instrument measured skin fold thickness (SFT) and compression rate (CR), finding that corticosteroids reduce both.
- Reduced CR and SFT correlated with a decrease in the skin's water/basic substance system, likely due to inhibited hyaluronic acid and glycosaminoglycan synthesis by fibroblasts.
- Atrophy and reduced CR normalized within 6-10 days after stopping steroid treatment, indicating a reversible process.
Impact:
- Provides a deeper understanding of the early biophysical and biochemical changes in steroid-induced dermal atrophy.
- Suggests that early atrophy is linked to alterations in the extracellular matrix hydration and synthesis.
- Highlights the reversibility of steroid-induced skin thinning, informing clinical management and patient counseling.